SCHEMBL29914603

SCHEMBL29914603

C[C@@H]1CN(c2ccc(Br)cn2)C[C@H](C)O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.51
POLB P06746 1/20 0.49
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44
AKR1C3 P42330 1/20 0.43
ACACB O00763 1/20 0.42
PDE10A Q9Y233 1/20 0.41
AOC3 Q16853 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 1/20 0.41
ADRA1A P35348 1/20 0.40
TLR9 Q9NR96 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11359952 1.00 KMT2A (0.51) KMT2APOLBGRIN2DGRIN3BGRIN1
SCHEMBL17803130 1.00 KMT2A (0.51) KMT2APOLBGRIN2DGRIN3BGRIN1
SCHEMBL17128421 1.00 KMT2A (0.51) KMT2APOLBGRIN2DGRIN3BGRIN1
SCHEMBL21588456 0.81 AKR1C3 (0.46) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21588286 0.81 AKR1C3 (0.46) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21588462 0.81 AKR1C3 (0.46) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL25686054 0.81 CNR2 (0.51) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21588445 0.81 GRIN2D (0.45) POLBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL24018507 0.81 KMT2A (0.53) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL31182223 0.81 KMT2A (0.53) KMT2AGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
WO-2022226667-A1 SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT KMT2A 1604/4885POLB 683/4885GRIN2D 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.